The Supreme Court has unanimously ruled that generic drugmakers cannot be sued for patent infringement simply because their marketing materials don’t spell out every limitation of their FDA approval — a decision that clears a significant legal cloud over a strategy used to bring cheaper drugs to market faster.
The June 4 ruling in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. resolves a dispute that had put a common generic drug launch strategy at risk. When a brand-name drug holds patents on some uses but not others, generic manufacturers can win FDA approval for only the unpatented uses — a so-called “skinny label” — and begin selling a cheaper version without waiting for all patents to expire. The approach has saved Medicare an estimated $15 billion between 2015 and 2021, according to a 2024 study in the Annals of Internal Medicine, and underlies nearly half of all first-to-market generic launches.
The case arose after Hikma Pharmaceuticals launched a generic version of Amarin’s heart drug Vascepa under a skinny label approved only for one use. Amarin sued, arguing that because Hikma described its product as a “generic version” of Vascepa in press releases and on its website — without flagging that it was approved for fewer uses — it was effectively nudging doctors to prescribe the drug for a still-patented indication.
The Supreme Court disagreed. Writing for a unanimous court, Justice Ketanji Brown Jackson said the law requires proof that a company actively pushed physicians toward the patented use, not just that a doctor could have drawn that inference on their own. Calling a product a “generic version” of a brand-name drug, or following standard industry marketing practices, isn’t enough to cross that line.
For hospital pharmacy leaders, the ruling matters beyond this one drug. A loss for Hikma would have made skinny labeling legally risky for generic manufacturers, likely delaying cheaper alternatives to brand-name drugs with multiple patents — and keeping costs higher for health systems and patients longer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
